RESMED INC (RMD) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $3.8M sold). Latest close $242.61 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 17, 2026 · Congress to Nov 16, 2026.
Giverny Capital — 1 tracked fund hold RMD. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 6 sales ($3.8M). Insider trading
BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Giverny Capital | 2.54% | 387,665 | ADDED (+68.5%) Q3 filed Nov 12 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +18.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 889 of 8,857 filers |
| Long-only filers among them | 884 |
| Change vs 2026 Q1 | -42 net · 806 entered · 848 exited |
| Shares reported, all filers | 99,318,112 |
| Reported value, all filers | $19.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Surgical & Medical Instruments & Apparatus (SIC 3841) |
| Revenue · FY2026 | $5.7B |
| Net income · FY2026 | $1.5B |
| Total assets · FY2026 | $9.0B |
| Shares outstanding | 144,252,306 |
| Market cap (at latest close) | $35.0B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 10, 2026.
| Shares short · Oct 15, 2026 | 11,920,328 |
| Share of shares outstanding | 8.26% |
| Days to cover | 12.33 |
Shares short at recent settlements — Jul 31, 2026: 15.7M · Aug 14, 2026: 12.8M · Aug 31, 2026: 13.1M · Sep 15, 2026: 14.2M · Sep 30, 2026: 12.8M · Oct 15, 2026: 11.9M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 10, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 10K · Sep 15, 2026: 84K · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 10, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 6 sales by 4 insiders ($3.8M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | De Witte Jan | Sell | 429 | $237.00 | $101.7K | SEC filing | |
| Nov 9, 2026 | Farrell Michael J. | Chairman and CEO | Sell | 4,993 | $235.35 | $1.2M | SEC filing |
| Oct 23, 2026 | Rider Michael J | Global General Counsel | Sell | 400 | $255.00 | $102.0K | SEC filing |
| Oct 7, 2026 | Farrell Michael J. | Chairman and CEO | Sell | 4,991 | $226.33 | $1.1M | SEC filing |
| Sep 8, 2026 | Farrell Michael J. | Chairman and CEO | Sell | 4,991 | $222.44 | $1.1M | SEC filing |
| Sep 2, 2026 | FARRELL PETER C | Sell | 970 | $234.73 | $227.7K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Oct 7, 2026 | Farrell Michael J. | Officer, Director | 4,991 | $1.1M | Oct 7, 2026 | SEC filing |
| Sep 8, 2026 | Farrell Michael J. | Officer, Director | 4,991 | $1.1M | Sep 8, 2026 | SEC filing |
| Sep 2, 2026 | Peter C Farrell | Director | 970 | $227.6K | Sep 2, 2026 | SEC filing |
| Aug 7, 2026 | Farrell Michael J. | Officer, Director | 4,991 | $1.0M | Aug 7, 2026 | SEC filing |
| Aug 5, 2026 | Peter C Farrell | Director | 8,000 | $1.8M | Aug 5, 2026 | SEC filing |
| Jul 7, 2026 | Farrell Michael J. | Officer, Director | 4,991 | $1.1M | Jul 7, 2026 | SEC filing |
| Jun 8, 2026 | Farrell Michael J. | Officer, Director | 4,991 | $968.3K | Jun 8, 2026 | SEC filing |
| May 27, 2026 | Sandercock Brett | Former Officer | 8,000 | $1.7M | May 27, 2026 | SEC filing |
| May 7, 2026 | Farrell Michael J. | Officer, Director | 4,991 | $1.0M | May 7, 2026 | SEC filing |
| Apr 7, 2026 | Farrell Michael J. | Officer, Director | 4,991 | $1.1M | Apr 7, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | AustralianSuper Pty Ltd | SC 13G | 8,276,381 | 5.7% | Jun 30, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Portfolio Management | SC 13G | 7,886,489 | 5.4% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 11,961,706.2 | 8.2% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Oct 30, 2025 | The Vanguard Group | SC 13G/A | 20,007,417.4 | 13.7% | Sep 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 100 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (57), Medicare/Medicaid (34), Manufacturing (7).
Federal contracts: $59.3K in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $121.4K |
| FY2022 | $0 |
| FY2023 | $-62.1K |
| FY2024 | $0 |
| FY2025 | $0 |
| FY2026 | $0 |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 75A50120C00055 | Department of Health and Human Services | $32.0M | Mar 31, 2020 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Buffett — Companies with high ROE sustained for more than a decade
· Growth — Revenue up every year for 5 straight years
· Graham — Sound finances and a long run of profits
· Piotroski — Financial health improved over the past year
· Greenblatt Magic Formula — High earnings yield and high return on capital together
· Lynch PEG — Cheap against its growth rate
· Dividend Growth — Dividends raised for more than 10 years
· Neff Total Return Ratio — Growth plus dividends divided by P/E is high
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
Red Flags
· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)
Key figures
· Buffett — Latest ROE: 23.1% · Years ROE ≥15% (of 10): 10 · 10-yr avg ROE: 20.6% · Latest net income: $1.5B
· Growth — Latest revenue: $5.7B · 5-yr revenue CAGR: 12.1% · Straight growth years: 9
· Graham — Current ratio: 3.10 · Straight profitable years: 18 · Debt ratio: 0.36 · Latest net income: $1.5B
· Piotroski — F-score: 7 · Return on assets: 17.0% · Operating cash flow: $1.8B
· Greenblatt Magic Formula — Earnings yield: 5.0% · Return on capital: 53.7% · Combined rank: 88
· Lynch PEG — P/E: 24.24 · 5-yr EPS growth: 26.3% · PEG: 0.92
· Dividend Growth — Dividend per share: 2.40 · Dividend yield: 0.9% · Straight dividend years: 14 · 10-yr dividend growth: 81.8%
· Neff Total Return Ratio — EPS growth: 26.3% · Dividend yield: 0.9% · P/E: 24.24 · Neff ratio: 1.13
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.27 · Operating cash flow: $1.8B · Net income: $1.5B
· Auditor Change (8-K 4.01) — Latest event: Aug 17, 2026 · Events in 2 yrs: 1
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold RMD — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Oct 29, 2026 | 2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Sep 1, 2026 | 8.01 Other Events | SEC filing |
| Aug 17, 2026 | 4.01 Changes in Registrant's Certifying Accountant · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on RMD
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.